Amicus Therapeutics, Inc. (NASDAQ:FOLD) Receives Consensus Rating of "Moderate Buy" from Analysts

Amicus Therapeutics, Inc. (NASDAQ:FOLD - Get Free Report) has been given an average rating of "Moderate Buy" by the ten ratings firms that are presently covering the company, MarketBeat.com reports. Three analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $16.22.

FOLD has been the subject of a number of recent analyst reports. UBS Group lifted their price objective on Amicus Therapeutics from $21.00 to $22.00 and gave the company a "buy" rating in a research report on Friday, May 2nd. Wells Fargo & Company decreased their target price on Amicus Therapeutics from $18.00 to $17.00 and set an "overweight" rating for the company in a research report on Thursday, February 20th. The Goldman Sachs Group decreased their target price on Amicus Therapeutics from $12.00 to $9.00 and set a "neutral" rating for the company in a research report on Friday, May 2nd. Needham & Company LLC reissued a "hold" rating on shares of Amicus Therapeutics in a report on Thursday, February 20th. Finally, Wall Street Zen cut Amicus Therapeutics from a "buy" rating to a "hold" rating in a research note on Monday, May 5th.

Amicus Therapeutics Price Performance

Shares of NASDAQ FOLD opened at $6.03 on Friday. The company has a debt-to-equity ratio of 2.01, a quick ratio of 2.42 and a current ratio of 3.39. Amicus Therapeutics has a fifty-two week low of $5.81 and a fifty-two week high of $12.65. The company has a market cap of $1.86 billion, a PE ratio of -33.50, a P/E/G ratio of 1.51 and a beta of 0.54. The business has a 50-day simple moving average of $6.48 and a two-hundred day simple moving average of $8.33.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the stock. Vanguard Group Inc. grew its holdings in shares of Amicus Therapeutics by 1.6% in the 4th quarter. Vanguard Group Inc. now owns 29,258,963 shares of the biopharmaceutical company's stock valued at $275,619,000 after buying an additional 458,143 shares during the period. Wellington Management Group LLP lifted its position in Amicus Therapeutics by 2.6% during the 1st quarter. Wellington Management Group LLP now owns 29,200,617 shares of the biopharmaceutical company's stock worth $238,277,000 after buying an additional 738,623 shares in the last quarter. Redmile Group LLC lifted its position in Amicus Therapeutics by 35.1% during the 1st quarter. Redmile Group LLC now owns 9,533,669 shares of the biopharmaceutical company's stock worth $77,795,000 after buying an additional 2,478,779 shares in the last quarter. Vestal Point Capital LP lifted its position in Amicus Therapeutics by 27.6% during the 1st quarter. Vestal Point Capital LP now owns 4,275,000 shares of the biopharmaceutical company's stock worth $34,884,000 after buying an additional 925,000 shares in the last quarter. Finally, Nuveen Asset Management LLC lifted its position in Amicus Therapeutics by 4.4% during the 4th quarter. Nuveen Asset Management LLC now owns 3,807,420 shares of the biopharmaceutical company's stock worth $35,866,000 after buying an additional 159,139 shares in the last quarter.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.